Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06369285
What this trial is testing

Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc. 225
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06548178
What this trial is testing

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Fudan University 242
Large-scale testing (Phase 3)Active Not RecruitingNCT04622319
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Who this might be right for
HER2-Positive Primary Breast CancerResidual Invasive Breast Cancer
Daiichi Sankyo 1,600
Large-scale testing (Phase 3)Not Yet RecruitingNCT05388500
What this trial is testing

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

Who this might be right for
HER2-positive Breast Cancer
Institut de cancérologie Strasbourg Europe 800
Not applicableApproved For MarketingNCT02792725
What this trial is testing

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Early research (Phase 1)Study completedNCT04132817
What this trial is testing

Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 12
Testing effectiveness (Phase 2)Study completedNCT00524303
What this trial is testing

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 100
Large-scale testing (Phase 3)Study completedNCT06009627
What this trial is testing

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 119
Large-scale testing (Phase 3)UnknownNCT04665986
What this trial is testing

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT02983604
What this trial is testing

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Who this might be right for
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Gilead Sciences 14
Large-scale testing (Phase 3)Study completedNCT00047255
What this trial is testing

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 263
Large-scale testing (Phase 3)Study completedNCT02040935
What this trial is testing

SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

Who this might be right for
Breast Cancer
Hoffmann-La Roche 128
Early research (Phase 1)Study completedNCT04398108
What this trial is testing

Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Zai Lab (Shanghai) Co., Ltd. 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT05708235
What this trial is testing

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Who this might be right for
Breast Cancer
MedSIR 976
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05501886
What this trial is testing

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Who this might be right for
Breast Cancer
Celcuity Inc 701
Early research (Phase 1)Ended earlyNCT00634088
What this trial is testing

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
R-Pharm 13
Early research (Phase 1)Study completedNCT03451162
What this trial is testing

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 14
Large-scale testing (Phase 3)Looking for participantsNCT06954961
What this trial is testing

Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 640
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Next Page